Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Russell 2000 ETF (IWM) vs Sana Biotechnology Inc (SANA) Price & Performance

iShares Russell 2000 ETFTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

iShares Russell 2000 ETF vs Sana Biotechnology Inc — how do they compare? iShares Russell 2000 ETF trades at $302.94, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: iShares Russell 2000 ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.

IWMSANA
52-Week High
$301.69$5.92
52-Week Low
$225.45$2.68
Market Cap
$1.13B
Sector
Health
Enterprise Value
$1.05B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Russell 2000 ETF

IWM (iShares Russell 2000 ETF) trades at $302.71, up 0.91% with a bullish technical signal from moving averages. The ETF, tracking 2,000 US small-cap stocks, shows strong institutional interest despite lacking traditional valuation ratios. Recent news highlights small-cap outperformance versus large caps, with institutional investors favoring IWM for its liquidity and options ecosystem. Technical indicators show RSI at 75 suggesting overbought conditions while ADX indicates a strong trend.

Outlook remains positive as small caps benefit from economic conditions, though high RSI suggests near-term consolidation risk. The ETF's broad small-cap exposure offers diversification but faces volatility from economic sensitivity. Institutional accumulation supports medium-term upside potential despite premium valuation concerns versus alternatives.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Russell 2000 ETF

The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on IWM

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA